SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Doorman who wrote (13868)2/23/1999 3:42:00 PM
From: M. LaMancha  Read Replies (1) | Respond to of 122088
 
Please note the following excerpt from the Globe story "EntreMed scientists are scheduled to report on recent progress in making large quantities of angiostatin and endostatin at today's sessions of the conference." I'm willing to bet it will be positive news. I think the expectation of the announcement could be what is driving this stock today.



To: Doorman who wrote (13868)2/23/1999 3:43:00 PM
From: Wes Stevens  Read Replies (2) | Respond to of 122088
 
I don't know much about this, but it does not look like that is good news for enmd. If Gene Medicine Inc. can get the same response using an injected gene, why do we need enmd's endostatin drug which is so hard to produce?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News